Further studies will be necessary to test for BMP6 responsive receptors on IFN-producing immune cells to see if ALK2/3 inhibitors alter their specific cytokine production profile in the context of Sjögren’s syndrome. This evidence concerns the gene IFNA1 and Sjogren syndrome.